CEL-SCI Corp's (CVM) Multikine Phase 3 Trial Receives FDA Clinical Hold

September 27, 2016 6:37 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

CEL-SCI Corporation (NYSE: CVM) announced that it has received verbal notice from the U.S. Food and Drug Administration (FDA) that its Multikine (Leukocyte Interleukin Injection) Phase 3 clinical trial in advanced primary head and neck cancer has been placed on clinical hold. Pursuant to this communication from FDA, patients currently receiving study treatments can continue to receive treatment, and patients already enrolled in the study will continue to be followed. CEL-SCI was also told to expect a formal letter from the FDA within 30 days and will work diligently with the FDA to obtain the release of the clinical hold. The study currently has about 926 patients enrolled.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Hot Corp. News, Hot FDA News

Add Your Comment